个人简介

Dr. Alison Moliterno is an associate professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hematologic disorders such as anemias, hemochromatosis, hypercoagulable states, iron deficiency, myeloproliferative disorders and thrombocytopenias. Dr. Moliterno completed her internal medicine training at Johns Hopkins Bayview and pursued her hematology clinical and research fellowships at the Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In 1998 she was awarded a prestigious Doris Duke Clinical Scientist Award and joined the Johns Hopkins faculty, and since then has directed numerous basic and translational projects in blood diseases. Dr. Moliterno maintains an active clinical and hospital consultation practice focused on the diagnosis and management of blood disorders. Dr. Moliterno received her medical degree from the State University of New York at Buffalo.

研究领域

Molecular pathogenesis of myeloproliferative disorders

Dr. Moliterno's major clinical research involves the study of the chronic myeloproliferative disorders (MPDs) including polycythemia vera, essential thrombocytosis and idiopathic myelofibrosis. Her research is focused on the genetic and epigenetic lesions associated with the MPDs with the goal of improving diagnosis and treatment for these disorders.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. New Engl J Med 338:572-580, 1998. Moliterno AR, Siebel K, Sun A, Hankins WD, Spivak JL. A novel thrombopoietin signaling defect in polycythemia vera platelets. Stem Cells 16(suppl 2):185-192, 1998. Moliterno AR, Spivak JL. Post-translational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood 94:2555-2561, 1999. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll R, Spivak JL. Mpl Baltimore: A Thrombopoietin Receptor Polymorphism Associated with Thrombocytosis. Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11444-7. Goerttler PS, Mrz E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, Marchioli R, Spivak JL, Pahl HL* for the MPD Research Consortium. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica 2005;90:851-853 Segal J, Moliterno AR. Platelet Counts Differ by Sex, Ethnicity, and Age in the United States. Ann Epidemiol. 2006 Feb;16(2):123-30 Moliterno AR, Williams D, Rogers O, Spivak JL. Molecular Mimicry in the Chronic Myeloproliferative Disorders: Reciprocity between Quantitative JAK2 V617F and Mpl Expression. Blood. 2006 Dec 1;108(12):3913-5. Pemmaraju N, Moliterno AR, Williams D, Rogers O, Spivak JL. Quantitative JAK2 V617F Neutrophil Allele Burden Does Not Correlate with Thrombotic Risk in Essential Thrombocytosis. Leukemia 2007 Oct;21(10):2210-2. Williams DR, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis and idiopathic myelofibrosis. Exp Hematol. 2007 Nov;35(11):1641-6. Moliterno AR, Williams D, Rogers O, Isaacs MA, Spivak JL Phenotypic variability within the JAK2 V617F-positive MPD: The roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008 Nov;36(11):1480-6.